Get the Stockscreener App
5.99
2.28%
-0.14
After Hours:
5.99
Amicus Therapeutics Inc stock is traded at $5.99, with a volume of 8.28M.
It is down -2.28% in the last 24 hours and up +4.54% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$6.13
Open:
$6.29
24h Volume:
8.28M
Relative Volume:
1.66
Market Cap:
$1.84B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-17.62
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
-4.62%
1M Performance:
+4.54%
6M Performance:
-37.47%
1Y Performance:
-41.90%
1-Day Range:
$5.97
$6.38
1-Week Range:
$5.97
$6.40
52-Week Range:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
5.99 | 1.89B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics: Q2 Earnings Snapshot - New Haven Register
Bank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PT - Insider Monkey
Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN
Amicus Therapeutics Q2 2025: Unraveling Contradictions in Revenue Impact, Trial Designs, and Market Dynamics - AInvest
Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda - MSN
Earnings call transcript: Amicus Therapeutics beats revenue forecast in Q2 2025 - Investing.com
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates - Yahoo.co
Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment? - simplywall.st
Amicus Therapeutics Q2 rev. $154.7mln, up 18% YoY, reiterates 2025 guidance. - AInvest
Amicus Therapeutics Q2 2025 revenue up 18% YoY to $154.7mln. - AInvest
Amicus Therapeutics Q2 2025 Financial Results and Corporate Updates - TradingView
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire Inc.
10 Best Strong Buy Stocks to Buy Under $10 - Insider Monkey
Pompe Disease Market Size 2034: EMA, PDMA, FDA Approval, - openPR.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legato Capital Management LLC - MarketBeat
Price Consolidation Hints at Upcoming Move in Amicus Therapeutics Inc.Community Shared Smart Money Signals Show Movement - metal.it
Victory Capital Management Inc. Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics FOLD 2025Q2 Earnings Preview Upside Potential with Strong Patient Demand Projection - AInvest
When is Amicus Therapeutics Inc. stock expected to show significant growthDaily Trading Guidance To Watch Now - jammulinksnews.com
What are Amicus Therapeutics Inc. company’s key revenue driversRapid wealth multiplication - jammulinksnews.com
Is Amicus Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough performance in the market - jammulinksnews.com
What is the dividend policy of Amicus Therapeutics Inc. stockAchieve fast wealth growth with smart picks - jammulinksnews.com
Amicus Therapeutics (FOLD) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionDiscover hidden gems in the stock market - jammulinksnews.com
Is it the right time to buy Amicus Therapeutics Inc. stockUnlock expert stock analysis and alerts - jammulinksnews.com
What makes Amicus Therapeutics Inc. stock price move sharplyROI Driven Alerts - metal.it
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - Insider Monkey
Amicus Therapeutics Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - PrintWeekIndia
How Amicus Therapeutics Inc. stock reacts to Fed policy changesFree Investment Portfolio Suggestions - jammulinksnews.com
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
What drives Amicus Therapeutics Inc. stock priceExceptional profit margins - Autocar Professional
Edgestream Partners L.P. Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
What analysts say about Amicus Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Published on: 2025-07-23 00:04:03 - jammulinksnews.com
Is Amicus Therapeutics Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewswire
Amicus Therapeutics Sets Date for Q2 Earnings: Key Updates Expected from Rare Disease Pipeline - Stock Titan
The Market Doesn't Like What It Sees From Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Yet - 富途牛牛
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Morgan Stanley - MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):